Skip to main content
SpringerLink
Log in
Book cover

Diabetes and Kidney Disease pp 175–201Cite as

Transplantation: Kidney, Kidney–Pancreas Transplant

  • Chapter
  • First Online:

  • 1935 Accesses

Abstract

With in-depth understanding of transplant immunology, more sensitive assays have been developed for immunological risk assessment, crossmatch, and detection of donor-specific antibodies. The discovery of potent immunosuppressive drugs has successfully reduced the risk of acute rejection and graft loss from rejection. Kidney transplant has become the preferred therapy for treating patient with ESRD. It not only improves the quality of life but also prolongs life. Living donor kidney transplant provides better allograft and patient survival than deceased donor kidney transplant. Novel approaches of living donor exchange and desensitization protocol have been increasingly used to facilitate ABO and/or HLA incompatible kidney transplant. Pancreas transplant, either simultaneously with a deceased donor kidney or after a living donor kidney transplant, has benefited many ESRD patients with insulin-dependent diabetes. Pancreas transplant alone can also be considered for Type 1 diabetes suffering life-threatening metabolic complication despite of insulin therapy. Modern immunosuppressive protocol typically includes an initial induction therapy with T-cell depleting antibody or IL-2 receptor antibody and a long-term maintenance. Maintenance regimen usually consists of two to three drugs of steroids, calcineurin inhibitor, antimetabolite, target-of-rapamycin inhibitor, or costimulation blocker. Careful monitoring and appropriate management of surgical and medical complications are the crucial part in post-transplant patient care, especially rejection, infection, metabolic syndrome, cardiovascular disease, and malignancy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Klein C, Brennan DC. HLA and ABO sensitization and desensitization in renal transplantation. UpToDate [Internet]. 2013. http://uptodate.medcity.net/. Accessed 16 March 2013.

  2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–29.

    CAS  PubMed  Google Scholar 

  3. Danovitch GM. Handbook of kidney transplantation. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 23–71.

    Google Scholar 

  4. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol. 2003;14(9):2402–10.

    PubMed  Google Scholar 

  5. Dinavahi R, George A, Tretin A, Akalin E, Ames S, Bromberg JS, Deboccardo G, Dipaola N, Lerner SM, Mehrotra A, Murphy BT, Nadasdy T, Paz-Artal E, Salomon DR, Schröppel B, Sehgal V, Sachidanandam R, Heeger PS. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol. 2011;22(6):1168–78.

    CAS  PubMed Central  PubMed  Google Scholar 

  6. Porcheray F, DeVito J, Yeap BY, Xue L, Dargon I, Paine R, Girouard TC, Saidman SL, Colvin RB, Wong W, Zorn E. Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation. 2010;89(10):1239–46.

    PubMed  Google Scholar 

  7. Montgomery RA. Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols. Am J Transplant. 2010;10:449–57.

    CAS  PubMed  Google Scholar 

  8. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91(6):2197–207.

    CAS  PubMed  Google Scholar 

  9. Scott DM, Ehrmann IE, Ellis PS, Chandler PR, Simpson E. Why do some females reject males? The molecular basis for male-specific graft rejection. J Mol Med (Berl). 1997;75(2):103–14.

    CAS  Google Scholar 

  10. Hankey KG, Drachenberg CB, Papadimitriou JC, Klassen DK, Philosophe B, Bartlett ST, Groh V, Spies T, Mann DL. MIC expression in renal and pancreatic allografts. Transplantation. 2002;73(2):304–6.

    CAS  PubMed  Google Scholar 

  11. Dragun D, Müller DN, Bräsen JH, Fritsche L, Nieminen-Kelhä M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schönemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558–69.

    CAS  PubMed  Google Scholar 

  12. Aguilera I, Alvarez-Marquez A, Gentil MA, Fernandez-Alonso J, Fijo J, Saez C, Wichmann I, Nuñez-Roldan A. Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients. Nephrol Dial Transplant. 2008;23(7):2393–8.

    CAS  PubMed  Google Scholar 

  13. Sun Q, Cheng Z, Cheng D, Chen J, Ji S, Wen J, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int. 2011;79(6):655–62.

    CAS  PubMed  Google Scholar 

  14. Khan IE, Zhang R, Simon E, Hamm LL. The alloimmune injury in chronic allograft nephropathy. In: Göőz M, editor. Chronic kidney disease. Rijeka: InTech; 2012. p. 401–14.

    Google Scholar 

  15. Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, Mancini D, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest. 1996;98(5):1150–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation. 1997; 64(6):795–800.

    CAS  PubMed  Google Scholar 

  17. Durrbach A, Francois H, Jacquet A, Beaudreuil S, Charpentier B. Co-signals in organ transplantation. Curr Opin Organ Transplant. 2010;15(4):474–80.

    PubMed  Google Scholar 

  18. Denton MD, Reul RM, Dharnidharka VR, Fang JC, Ganz P, Briscoe DM. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Pediatr Transplant. 1998;2(1):6–15.

    CAS  PubMed  Google Scholar 

  19. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3):443–53.

    CAS  PubMed  Google Scholar 

  20. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170(6):2081–95.

    CAS  PubMed  Google Scholar 

  21. Tsaur I, Gasser M, Aviles B, Lutz J, Lutz L, Grimm M, et al. Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney Int. 2011;79(9):1005–12.

    CAS  PubMed  Google Scholar 

  22. Mills DM, Cambier JC. B lymphocyte activation during cognate interactions with CD4+ T lymphocytes: molecular dynamics and immunologic consequences. Semin Immunol. 2003;15(6):325–9.

    CAS  PubMed  Google Scholar 

  23. Richards S, Watanabe C, Santos L, Craxton A, Clark EA. Regulation of B-cell entry into the cell cycle. Immunol Rev. 2008;224:183–200.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Gatto D, Martin SW, Bessa J, Pellicioli E, Saudan P, Hinton HJ, et al. Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol. 2007;178(1):67–76.

    CAS  PubMed  Google Scholar 

  25. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805–20.

    CAS  PubMed  Google Scholar 

  26. Ren Q, Paramesh AS, Yau CL, Florman S, Killackey M, Slakey DP, Alper B, Simon E, Hamm LL, Zhang R. Kidney transplantation in highly sensitized African Americans. Transpl Int. 2011;24(3):259–65.

    PubMed  Google Scholar 

  27. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation. 2005;79(6):696–701.

    PubMed  Google Scholar 

  28. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365(4):318–26.

    CAS  PubMed  Google Scholar 

  29. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006;6(2):346–51.

    CAS  PubMed  Google Scholar 

  30. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242–51.

    CAS  PubMed  Google Scholar 

  31. Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant. 2004;4(4):561–8.

    PubMed  Google Scholar 

  32. US Department of Health and Human Services. 2011 Annual report of the organ procurement and transplantation network and the scientific registry of transplant recipients. Am J Transplant. 2013;13(S1):1–36.

    Google Scholar 

  33. Chouhan K, Zhang R. Editorial review: antibody induction therapy in adult kidney transplantation, a controversy continues. World J Transplant. 2012;2(2):19–26.

    PubMed Central  PubMed  Google Scholar 

  34. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss Jr H, Rubin RH. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation. 1992;53(1):68–72.

    CAS  PubMed  Google Scholar 

  35. Thistlethwaite Jr JR, Stuart JK, Mayes JT, Gaber AO, Woodle S, Buckingham MR, Stuart FP. Complications and monitoring of OKT3 therapy. Am J Kidney Dis. 1988;11(2):112–9.

    PubMed  Google Scholar 

  36. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323(25):1723–8.

    CAS  PubMed  Google Scholar 

  37. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Singer GG. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67(7):1011–8.

    CAS  PubMed  Google Scholar 

  38. Hardinger KL, Schnitzler MA, Miller B, Lowell JA, Shenoy S, Koch MJ, Enkvetchakul D, Ceriotti C, Brennan DC. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation. 2004;78(1):136–41.

    CAS  PubMed  Google Scholar 

  39. Hardinger KL, Rhee S, Buchanan P, Koch M, Miller B, Enkvetchakul D, Schuessler R, Schnitzler MA, Brennan DC. A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation. 2008;86(7):947–52.

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Goggins WC, Pascual MA, Powelson JA, Magee C, Tolkoff-Rubin N, Farrell ML, Ko DS, Williams WW, Chandraker A, Delmonico FL, Auchincloss H, Cosimi AB. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation. 2003;76(5):798–802.

    CAS  PubMed  Google Scholar 

  41. Wong W, Agrawal N, Pascual M, Anderson DC, Hirsch HH, Fujimoto K, Cardarelli F, Winkelmayer WC, Cosimi AB, Tolkoff-Rubin N. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int. 2006;19(8):629–35.

    CAS  PubMed  Google Scholar 

  42. Stevens RB, Mercer DF, Grant WJ, Freifeld AG, Lane JT, Groggel GC, Rigley TH, Nielsen KJ, Henning ME, Skorupa JY, Skorupa AJ, Christensen KA, Sandoz JP, Kellogg AM, Langnas AN, Wrenshall LE. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation. 2008;85(10): 1391–9.

    CAS  PubMed  Google Scholar 

  43. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338:161–5.

    CAS  PubMed  Google Scholar 

  44. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67:276–84.

    CAS  PubMed  Google Scholar 

  45. Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 2003;75:37–43.

    CAS  PubMed  Google Scholar 

  46. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: a meta analysis of randomized trials. Transplantation. 2004;77: 166–76.

    CAS  PubMed  Google Scholar 

  47. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant. 2006;6(5 Pt 1):1084–5.

    CAS  PubMed  Google Scholar 

  48. Pascual J, Mezrich JD, Djamali A, Leverson G, Chin LT, Torrealba J, Bloom D, Voss B, Becker BN, Knechtle SJ, Sollinger HW, Pirsch JD, Samaniego MD. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation. 2007;83(11):1429–34.

    CAS  PubMed  Google Scholar 

  49. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J, for the INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909–19.

    CAS  PubMed  Google Scholar 

  50. Tan HP, Donaldson J, Basu A, Unruh M, Randhawa P, Sharma V, Morgan C, McCauley J, Wu C, Shah N, Zeevi A, Shapiro R. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant. 2009;9(2):355–66.

    CAS  PubMed  Google Scholar 

  51. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction—long-term results. Am J Transplant. 2005;5(10):2539–48.

    CAS  PubMed  Google Scholar 

  52. Flechner SM, Friend PJ, Brockmann J, Ismail HR, Zilvetti M, Goldfarb D, Modlin C, Mastroianni B, Savas K, Devaney A, Simmonds M, Cook DJ. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant. 2005;5: 3009–14.

    CAS  PubMed  Google Scholar 

  53. Mulley WR, Hudson FJ, Tait BD, Skene AM, Dowling JP, Kerr PG, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation. 2009;87(2):286–9.

    CAS  PubMed  Google Scholar 

  54. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–155.

    Google Scholar 

  55. Jindal RM, Das NP, Neff RT, Hurst FP, Falta EM, Elster EA, Abbott KC. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 inhibitor induction: analysis of USRD database. Am J Nephrol. 2009;29:501–8.

    CAS  PubMed  Google Scholar 

  56. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967–77.

    CAS  PubMed  Google Scholar 

  57. Patlolla V, Zhong X, Reed GW, Mandelbrot DA. Efficacy of anti IL2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant. 2007;7:832–1842.

    Google Scholar 

  58. Luan FL, Schaubel DE, Zhang H, Jia X, Pelletier SJ, Port FK, Magee JC, Sung RS. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation. 2008;85(11):1601–6.

    CAS  PubMed  Google Scholar 

  59. Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–14.

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Patel SJ, Knight RJ, Suki WN, Abdellatif A, Duhart Jr BT, Krauss AG, Mannan S, Nezakatgoo N, Osama GA. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant. 2011;25(3):E250–6.

    PubMed  Google Scholar 

  61. Morton RL, Howard K, Webster AC, Wong G, Craig JC. The cost effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant. 2009;24(7):2258–69.

    PubMed  Google Scholar 

  62. Leichtman AB. Balancing efficacy and toxicity in kidney-transplant immunosuppression. N Engl J Med. 2007;357(25): 2625–7.

    CAS  PubMed  Google Scholar 

  63. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation. 1994;57(7):979–89.

    CAS  PubMed  Google Scholar 

  64. Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15(12):3233–9.

    PubMed  Google Scholar 

  65. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med. 1986;314(19):1219–25.

    Google Scholar 

  66. Mueller EA, Kovarik JM, van Bree JB, Lison AE, Kutz K. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients—a concentration-controlled comparison with the commercial formulation. Transplantation. 1994;57(8):1178–82.

    CAS  PubMed  Google Scholar 

  67. Pescovitz MD, Barone G, Choc Jr MG, Hricik DE, Hwang DS, Jin JH, et al. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group. Transplantation. 1997;63(5):778–80.

    CAS  PubMed  Google Scholar 

  68. Ponticelli C, Minetti L, Di Palo FQ, Vegeto A, Belli L, Corbetta G, et al. The Milan clinical trial with cyclosporine in cadaveric renal transplantation. A three-year follow-up. Transplantation. 1988;45(5):908–13.

    CAS  PubMed  Google Scholar 

  69. Knight SR, Morris PJ. The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation. 2007;83(12):1525–35.

    CAS  PubMed  Google Scholar 

  70. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ. 1999;318(7191):1104–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  71. Hardinger KL, Bohl DL, Schnitzler MA, Lockwood M, Storch GA, Brennan DC. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. Transplantation. 2005;80(1):41–6.

    CAS  PubMed  Google Scholar 

  72. Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet. 2002; 359(9308):741–6.

    CAS  PubMed  Google Scholar 

  73. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331(7520):810.

    CAS  PubMed Central  PubMed  Google Scholar 

  74. Krämer BK, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Ortuño J, Sester U, Kunzendorf U, Dietl KH, Bonomini V, Rigotti P, Ronco C, Tabernero JM, Rivero M, Banas B, Mühlbacher F, Arias M, Montagnino G. Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant. 2008;23(7):2386–92.

    PubMed  Google Scholar 

  75. Silva Jr HT, Yang HC, Abouljoud M, Kuo PC, Wisemandle K, Bhattacharya P, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7(3):595–608.

    CAS  PubMed  Google Scholar 

  76. Bergan S, Rugstad HE, Bentdal O, Sodal G, Hartmann A, Leivestad T, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation. 1998;66(3):334–9.

    CAS  PubMed  Google Scholar 

  77. Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol. 2007;18(6):1973–85.

    CAS  PubMed  Google Scholar 

  78. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000; 356(9225):194–202.

    CAS  PubMed  Google Scholar 

  79. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant. 2003;3(1):68–73.

    CAS  PubMed  Google Scholar 

  80. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1997;64(9):1277–82.

    PubMed  Google Scholar 

  81. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60(3):225–32.

    CAS  PubMed  Google Scholar 

  82. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61(7):1029–37.

    Google Scholar 

  83. Kofler S, Shvets N, Bigdeli AK, Konig MA, Kaczmarek P, Deutsch MA, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients—a prospective case-controlled study. Am J Transplant. 2009;9(7):1650–6.

    CAS  PubMed  Google Scholar 

  84. Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit. 2011;33(1):120–3.

    CAS  PubMed  Google Scholar 

  85. Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L, et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation. 2007;84(11):1443–51.

    CAS  PubMed  Google Scholar 

  86. Bunnapradist S, Lentine KL, Burroughs TE, Pinsky BW, Hardinger KL, Brennan DC, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation. 2006;82(1):102–7.

    CAS  PubMed  Google Scholar 

  87. Langone AJ, Chan L, Bolin P, Cooper M. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation. 2011;91(4):470–8.

    CAS  PubMed  Google Scholar 

  88. Chong AS, Zeng H, Knight DA, Shen J, Meister GT, Williams JW, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant. 2006;6(1):69–75.

    CAS  PubMed  Google Scholar 

  89. Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, Foster P, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation. 2006;81(5):704–10.

    CAS  PubMed  Google Scholar 

  90. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036–42.

    CAS  PubMed  Google Scholar 

  91. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005;5(9):2273–80.

    CAS  PubMed  Google Scholar 

  92. Meier-Kriesche HU, Steffen BJ, Chu AH, Loveland JJ, Gordon RD, Morris JA, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant. 2004;4(12):2058–66.

    CAS  PubMed  Google Scholar 

  93. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377(9768):837–47.

    CAS  PubMed  Google Scholar 

  94. Ciancio G, Burke GW, Gaynor JJ, Ruiz P, Roth D, Kupin W, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation. 2006;81(6):845–52.

    CAS  PubMed  Google Scholar 

  95. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353(8):770–81.

    CAS  PubMed  Google Scholar 

  96. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547–57.

    CAS  PubMed  Google Scholar 

  97. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535–46.

    CAS  PubMed  Google Scholar 

  98. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran PF, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9):1587–96.

    PubMed Central  PubMed  Google Scholar 

  99. Toyoda M, Pao A, Petrosian A, Jordan SC. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant. 2003;3(2):156–66.

    CAS  PubMed  Google Scholar 

  100. Luke PP, Scantlebury VP, Jordan ML, Vivas CA, Hakala TR, Jain A, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation. 2001;72(3):419–22.

    CAS  PubMed  Google Scholar 

  101. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation. 2003;75(9):1490–5.

    CAS  PubMed  Google Scholar 

  102. Casadei DH, del C Rial M, Opelz G, Golberg JC, Argento JA, Greco G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001;71(1):53–8.

    Google Scholar 

  103. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754–61.

    CAS  PubMed  Google Scholar 

  104. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9(1):231–5.

    CAS  PubMed  Google Scholar 

  105. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant. 2008;8(2):307–16.

    CAS  PubMed  Google Scholar 

  106. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248(4):564–77.

    PubMed  Google Scholar 

  107. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J, INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20):1909–19.

    CAS  PubMed  Google Scholar 

  108. Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol. 2012;7(3):504–12.

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Heilman RL, Younan K, Wadei HM, Mai ML, Reddy KS, Chakkera HA, et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation. 2011;92(7):767–73.

    CAS  PubMed  Google Scholar 

  110. Ekberg H, Grinyó J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant. 2007;7(3):560–70.

    CAS  PubMed  Google Scholar 

  111. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–75.

    CAS  PubMed  Google Scholar 

  112. Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876–85.

    CAS  PubMed  Google Scholar 

  113. Guerra G, Ciancio G, Gaynor JJ, Zarak A, Brown R, Hanson L, et al. Randomized trial of immunosuppressive regimens in renal transplantation. J Am Soc Nephrol. 2011;22(9):1758–68.

    CAS  PubMed Central  PubMed  Google Scholar 

  114. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant. 2007;7(3):586–94.

    CAS  PubMed  Google Scholar 

  115. Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int. 2011;79(8):897–907.

    CAS  PubMed  Google Scholar 

  116. Flechner SM, Glyda M, Cockfield S, Grinyo J, Legendre C, Russ G, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant. 2011;11(8):1633–44.

    CAS  PubMed  Google Scholar 

  117. Steinman TI, Becker BN, Frost AE, Olthoff KM, Smart FW, Suki WN, Wilkinson AH, Clinical Practice Committee, American Society of Transplantation. Guidelines for the referral and management of patients eligible for solid organ transplantation. Transplantation. 2001;71(9):1189–204.

    CAS  PubMed  Google Scholar 

  118. Kasiske BL, Ramos EL, Gaston RS, Bia MJ, Danovitch GM, Bowen PA, Lundin PA, Murphy KJ. The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol. 1995;6(1):1–34.

    CAS  PubMed  Google Scholar 

  119. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55(4):742–7.

    CAS  PubMed  Google Scholar 

  120. Tavakoli A, Surange RS, Pearson RC, Parrott NR, Augustine T, Riad HN. Impact of stents on urologic complications and health care expenditure in renal transplant recipients: results of a prospective, randomized clinical trial. J Urol. 2007;177(6):2260–4.

    CAS  PubMed  Google Scholar 

  121. Mandelbrot DA, Pavlakis M, Danovitch GM, Johnson SR, Karp SJ, Khwaja K, Hanto DW, Rodrigue JR. The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transplant. 2007;7(10):2333–43.

    CAS  PubMed  Google Scholar 

  122. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, Halloran PF, Baldwin W, Banfi G, Collins AB, Cosio F, David DS, Drachenberg C, Einecke G, Fogo AB, Gibson IW, Glotz D, Iskandar SS, Kraus E, Lerut E, Mannon RB, Mihatsch M, Nankivell BJ, Nickeleit V, Papadimitriou JC, Randhawa P, Regele H, Renaudin K, Roberts I, Seron D, Smith RN, Valente M. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753–60.

    CAS  PubMed  Google Scholar 

  123. Mauiyyedi S, Crespo M, Collins AB, Schneeberger EE, Pascual MA, Saidman SL. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol. 2002;13(3):779–87.

    PubMed  Google Scholar 

  124. Saidi RF, Elias N, Kawai T, Hertl M, Farrell ML, Goes N. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant. 2007;7(12):2769–74.

    CAS  PubMed  Google Scholar 

  125. Humar A, Matas AJ. Surgical complications after kidney transplantation. Semin Dial. 2005;18(6):505–10.

    PubMed  Google Scholar 

  126. Shinn C, Malhotra D, Chan L, Cosby RL, Shapiro JI. Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. Am J Kidney Dis. 1999;34(2):304–7.

    CAS  PubMed  Google Scholar 

  127. Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ. Oral versus intravenous high-dose steroid treatment of renal allograft rejection. The big shot or not? Lancet. 1978;1(8056):117–8.

    CAS  PubMed  Google Scholar 

  128. Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, Mulloy LL, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998;66(1):29–37.

    CAS  PubMed  Google Scholar 

  129. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006;81(7):953–65.

    CAS  PubMed  Google Scholar 

  130. Worthington JE, McEwen A, McWilliam LJ, Picton ML, Martin S. Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation. 2007;83(4):398–403.

    PubMed  Google Scholar 

  131. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant. 2012;12(3):563–70.

    CAS  PubMed Central  PubMed  Google Scholar 

  132. Troxell ML, Weintraub LA, Higgins JP, Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin J Am Soc Nephrol. 2006;1(3):583–91.

    PubMed  Google Scholar 

  133. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant. 2004;4(6):996–1001.

    CAS  PubMed  Google Scholar 

  134. Locke JE, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant. 2007;7(4):842–6.

    CAS  PubMed  Google Scholar 

  135. Opelz G, Dohler B, Collaborative Transplant Study Report. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation. 2008;85(5):661–6.

    PubMed  Google Scholar 

  136. Madden RL, Mulhern JG, Benedetto BJ, O'Shea MH, Germain MJ, Braden GL, et al. Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients. Transpl Int. 2000;13(5):344–50.

    CAS  PubMed  Google Scholar 

  137. Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996;62(5):594–9.

    CAS  PubMed  Google Scholar 

  138. Briggs D, Dudley C, Pattison J, Pfeffer P, Salmela K, Rowe P, et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. Transplantation. 2003;75(12):2058–63.

    CAS  PubMed  Google Scholar 

  139. Clatworthy MR, Friend PJ, Calne RY, Rebello PR, Hale G, Waldmann H, et al. Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation. 2009;87(7):1092–5.

    CAS  PubMed  Google Scholar 

  140. Csapo Z, Benavides-Viveros C, Podder H, Pollard V, Kahan BD. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc. 2005;37(5):2032–6.

    CAS  PubMed  Google Scholar 

  141. Wahl AO, Small Jr W, Dixler I, Strom S, Rademaker A, Leventhal J, et al. Radiotherapy for rejection of renal transplant allografts refractory to medical immunosuppression. Am J Clin Oncol. 2006;29(6):551–4.

    PubMed  Google Scholar 

  142. Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007;7(11):2538–45.

    CAS  PubMed  Google Scholar 

  143. Nemeth D, Ovens J, Opelz G, Sommerer C, Dohler B, Becker LE, et al. Does borderline kidney allograft rejection always require treatment? Transplantation. 2010;90(4):427–32.

    PubMed  Google Scholar 

  144. Seron D, Moreso F. Protocol biopsies in renal transplantation: prognostic value of structural monitoring. Kidney Int. 2007;72(6):690–7.

    CAS  PubMed  Google Scholar 

  145. Zhang R, Lia J, Morse S, Donelon S, Reisin E. Kidney disease in the metabolic syndrome. Am J Med Sci. 2005;330(6):319–25.

    PubMed  Google Scholar 

  146. Zhang R, Thakur V, Morse S, Reisin E. Renal and cardiovascular considerations for the non pharmacological and pharmacological therapies of obesity-hypertension. J Hum Hypertens. 2002;16(12): 819–27.

    CAS  PubMed  Google Scholar 

  147. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–74.

    PubMed  Google Scholar 

  148. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793–808.

    PubMed  Google Scholar 

  149. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2001;16:2386–94.

    CAS  PubMed  Google Scholar 

  150. Molnar MZ, Streja E, Kovesday CP, Bunnapradist S, Sampaio MS, Jing J, Krishnan M, Nissenson AR, Danovitch GM, Kalantar-Zadeh K. Associations of body mass index and weight loss with mortality in transplant waitlisted maintenance of hemodialysis patients. Am J Transplant. 2011;11:725–36.

    CAS  PubMed Central  PubMed  Google Scholar 

  151. Chang SH, Coates PT, McDonald SP. Effects of body mass index at transplant on outcomes of kidney transplantation. Transplantation. 2007;84:981–7.

    PubMed  Google Scholar 

  152. Molnar MZ, Kovesdy CP, Musci I, Bunnapradist S, Streja E, Krishnan M, Kalantar-Zadeh K. Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int. 2011;80:218–24.

    PubMed  Google Scholar 

  153. Meier-Kriesche H, Arndorfer J, Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002;73:70–4.

    PubMed  Google Scholar 

  154. Friedman AN, Miskulin DC, Rosenberg IH. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis. 2003;41:480–7.

    PubMed  Google Scholar 

  155. Glanton C, Kao T, Cruess D, Agodoa LY, Abbott KC. Impact of renal transplantation on survival in end-stage renal disease with elevated body mass index. Kidney Int. 2003;63:647–53.

    PubMed  Google Scholar 

  156. Kovas AZ, Molnar MZ, Szeifert L. Sleep disorders, depressive symptoms and health related quality of life—a cross sectional comparison between kidney transplant recipients and waitlisted patients on maintenance dialysis. Nephrol Dial Transplant. 2011;26(3):1058–65.

    Google Scholar 

  157. Johnson CP, Gallagher-Lepak S, Zhu YR, et al. Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822–7.

    CAS  PubMed  Google Scholar 

  158. Hoogeveen EK, Aalten J, Rothman KJ, Roodnat JI, et al. Effect of obesity on the outcome of kidney transplantation: a 20 year follow up. Transplantation. 2011;91:869–74.

    PubMed  Google Scholar 

  159. Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69:2227–43.

    PubMed  Google Scholar 

  160. Miller L. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;1:807–18.

    Google Scholar 

  161. Ducloux D, Kazory A, Chalopin JM. Post transplant diabetes mellitus and atherosclerotic events in renal transplant recipients: A prospective study. Transplantation. 2005;79:438–43.

    PubMed  Google Scholar 

  162. Kasiske B, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–85.

    PubMed  Google Scholar 

  163. Nathaniel B, Cochetti P, Mysore S, et al. Association of metabolic syndrome with development of new-onset diabetes after transplant. Transplantation. 2010;90:861–6.

    Google Scholar 

  164. Ajay I, Snyder J, Skeans M, et al. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int. 2012;25:748–75.

    Google Scholar 

  165. Larsen CP, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90:1528–35.

    CAS  PubMed  Google Scholar 

  166. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12(3):630–9.

    CAS  PubMed  Google Scholar 

  167. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients. Transplantation. 2011;91(9):976–83.

    CAS  PubMed  Google Scholar 

  168. The AST infectious disease community of practice, American Society of Transplantation, infectious disease guidelines 3rd edition. Am J Transplant. 2013;13 Suppl 4:3–336.

    Google Scholar 

  169. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601–14.

    CAS  PubMed  Google Scholar 

  170. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother. 1998;42(5):995–1004.

    CAS  PubMed Central  PubMed  Google Scholar 

  171. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488–96.

    PubMed  Google Scholar 

  172. Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int. 2009;22(6):626–34.

    PubMed  Google Scholar 

  173. Nickeleit V, Hirsch HH, Zeiler M, Gudat F, Prince O, Thiel G, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant. 2000;15(3):324–32.

    CAS  PubMed  Google Scholar 

  174. McGilvray ID, Lajoie G, Humar A, Cattral MS. Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry? Am J Transplant. 2003;3(4):501–4.

    PubMed  Google Scholar 

  175. Kuypers DR, Vandooren AK, Lerut E, Evenepoel P, Claes K, Snoeck R, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant. 2005;5(8):1997–2004.

    CAS  PubMed  Google Scholar 

  176. Vats A, Shapiro R, Singh Randhawa P, Scantlebury V, Tuzuner A, Saxena M, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation. 2003;75(1):105–12.

    CAS  PubMed  Google Scholar 

  177. Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010;5(7):1298–304.

    CAS  PubMed Central  PubMed  Google Scholar 

  178. Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40(4):528–37.

    CAS  PubMed  Google Scholar 

  179. Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation. 2006;81(1):117–20.

    CAS  PubMed  Google Scholar 

  180. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation. 2004;78(7):1069–73.

    CAS  PubMed  Google Scholar 

  181. Dharnidharka VR, Cherikh WS, Neff R, Cheng Y, Abbott KC. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant. 2010;10(5):1312–5.

    CAS  PubMed  Google Scholar 

  182. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2001;12(4):848–55.

    CAS  PubMed  Google Scholar 

  183. Reinke P, Fietze E, Ode-Hakim S, Prosch S, Lippert J, Ewert R, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994;344(8939–8940):1737–8.

    Google Scholar 

  184. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis. 1999;1(S1):8–12.

    PubMed  Google Scholar 

  185. Kotton CN, Kumar D, Caliendo AM. International consensus guidelines on the management of cytomegalovirus infection in solid organ transplantation. Transplantation. 2010;89:775–95.

    Google Scholar 

  186. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48(6):772–86.

    CAS  PubMed  Google Scholar 

  187. Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69–77.

    CAS  PubMed  Google Scholar 

  188. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8(5):975–83.

    CAS  PubMed  Google Scholar 

  189. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10(5):1228–37.

    CAS  PubMed  Google Scholar 

  190. Reischig T, Hribova P, Jindra P, Hes O, Bouda M, Treska V, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2012;23(9):1588–97.

    CAS  PubMed Central  PubMed  Google Scholar 

  191. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–13.

    CAS  PubMed  Google Scholar 

  192. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Sakamoto K, Purtilo DT, Balfour Jr HH, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982;306(15):913–8.

    CAS  PubMed  Google Scholar 

  193. Cavaliere R, Petroni G, Lopes MB, Schiff D, International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116(4):863–70.

    PubMed  Google Scholar 

  194. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 1998;16(6):2052–9.

    CAS  PubMed  Google Scholar 

  195. Rajakariar R, Bhattacharyya M, Norton A, Sheaff M, Cavenagh J, Raftery MJ, et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant. 2004;4(9):1534–8.

    PubMed  Google Scholar 

  196. Bakker NA, Pruim J, de Graaf W, van Son WJ, van der Jagt EJ, van Imhoff GW. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant. 2006;6(8): 1984–5.

    CAS  PubMed  Google Scholar 

  197. Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC, Olthoff KM, Schuster SJ, Nasta SD, Stadtmauer EA, Tsai DE. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6(3):569–76.

    CAS  PubMed  Google Scholar 

  198. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196–206.

    CAS  PubMed  Google Scholar 

  199. Salgo R, Gossmann J, Schofer H, Kachel HG, Kuck J, Geiger H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10(6):1385–93.

    CAS  PubMed  Google Scholar 

  200. Vaysberg M, Balatoni CE, Nepomuceno RR, Krams SM, Martinez OM. Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation. 2007;83(8):1114–21.

    CAS  PubMed  Google Scholar 

  201. Dantal J, Soulillou JP. Immunosuppressive drugs and the risk of cancer after organ transplantation. N Engl J Med. 2005;352(13): 1371–3.

    CAS  PubMed  Google Scholar 

  202. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005;80(2 Suppl):S254–64.

    PubMed  Google Scholar 

  203. Engels EA, Pfeiffer RM, Fraumeni Jr JF, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901.

    CAS  PubMed Central  PubMed  Google Scholar 

  204. Zou S, Dodd RY, Stramer SL, Strong DM, Tissue Safety Study Group. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med. 2004;351(8):751–9.

    CAS  PubMed  Google Scholar 

  205. Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis. 2012;55(5):720–7.

    PubMed  Google Scholar 

  206. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.

    PubMed  Google Scholar 

  207. Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol. 2007;2(4):750–6.

    PubMed  Google Scholar 

  208. Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329–39.

    CAS  PubMed  Google Scholar 

  209. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17(2):581–9.

    CAS  PubMed  Google Scholar 

  210. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967;61(6):827–37.

    CAS  PubMed  Google Scholar 

  211. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med. 1994;11(3):299–303.

    CAS  PubMed  Google Scholar 

  212. Saudek F, Průhová S, Boucek P, Lebl J, Adamec M, Ek J, Pedersen O, Hansen T. Maturity onset diabetes of the young with end stage nephropathy: a new indication for simultaneous pancreas and kidney transplantation? Transplantation. 2004;77(8): 1298–301.

    PubMed  Google Scholar 

  213. Robertson RP, Davis C, Larsen J, Stratta R, Sutherland DER. Pancreas and islet transplantation in type I diabetes. Diabetes Care. 2006;29(4):935.

    PubMed  Google Scholar 

  214. www.srtr.org. Accessed 15 April 2013.

  215. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–8.

    CAS  PubMed  Google Scholar 

  216. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060–9.

    CAS  PubMed  Google Scholar 

  217. Senior PA, Zeman M, Paty BW, Ryan EA, Shapiro AM. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant. 2007;7(1):91–8.

    CAS  PubMed  Google Scholar 

  218. Campbell PM, Senior PA, Salam A, LaBranche K, Bigam DL, Kneteman NM, Imes S, Halpin A, Ryan EA, Shapiro AM. High risk of sensitization after failed islet transplantation. Am J Transplant. 2007;7(10):2311–7.

    CAS  PubMed  Google Scholar 

  219. Sutherland DE, Gruessner R, Dunn D, Moudry-Munns K, Gruessner A, Najarian JS. Pancreas transplants from living-related donors. Transplant Proc. 1994;26(2):443–5.

    CAS  PubMed  Google Scholar 

  220. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A. 2006;103(46):17438–43.

    CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, SL-45, New Orleans, LA, 70112, USA

    Rubin Zhang

  2. Departments of Surgery and Urology, Tulane Abdominal Transplant Institute, Tulane University School of Medicine, New Orleans, LA, USA

    Anil Paramesh

Authors
  1. Rubin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anil Paramesh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rubin Zhang .

Editor information

Editors and Affiliations

  1. University of Illinois, Chicago, Illinois, USA

    Edgar V. Lerma

  2. Nephrology Section, Tulane University Medical School, New Orleans, Louisiana, USA

    Vecihi Batuman

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Zhang, R., Paramesh, A. (2014). Transplantation: Kidney, Kidney–Pancreas Transplant. In: Lerma, E., Batuman, V. (eds) Diabetes and Kidney Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0793-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0793-9_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0792-2

  • Online ISBN: 978-1-4939-0793-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation